AU2018348930A1 - Bicyclic compounds for use as RIP 1 kinase inhibitors - Google Patents
Bicyclic compounds for use as RIP 1 kinase inhibitors Download PDFInfo
- Publication number
- AU2018348930A1 AU2018348930A1 AU2018348930A AU2018348930A AU2018348930A1 AU 2018348930 A1 AU2018348930 A1 AU 2018348930A1 AU 2018348930 A AU2018348930 A AU 2018348930A AU 2018348930 A AU2018348930 A AU 2018348930A AU 2018348930 A1 AU2018348930 A1 AU 2018348930A1
- Authority
- AU
- Australia
- Prior art keywords
- fluoro
- phenyl
- dihydro
- pyrrolo
- triazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C[C@@](C1)C2=*C(C#CC3CC3)=**2[C@@]1c1ccccc1 Chemical compound C[C@@](C1)C2=*C(C#CC3CC3)=**2[C@@]1c1ccccc1 0.000 description 3
- FRAKFBWDPXYIQO-UHFFFAOYSA-N Brc1nc(Br)n[nH]1 Chemical compound Brc1nc(Br)n[nH]1 FRAKFBWDPXYIQO-UHFFFAOYSA-N 0.000 description 1
- OUOQLEMKKVUYLC-UHFFFAOYSA-N Brc1nc(Br)n[n]1C1OCCCC1 Chemical compound Brc1nc(Br)n[n]1C1OCCCC1 OUOQLEMKKVUYLC-UHFFFAOYSA-N 0.000 description 1
- SUMITXYKWKMQLD-HQVZTVAUSA-N C=C(C1)c2nc(CC(C3)C3(F)F)n[n]2[C@@H]1c(cccc1)c1F Chemical compound C=C(C1)c2nc(CC(C3)C3(F)F)n[n]2[C@@H]1c(cccc1)c1F SUMITXYKWKMQLD-HQVZTVAUSA-N 0.000 description 1
- CJSNDSAMJUXZLL-NSHDSACASA-N C=Cc1n[n]([C@@H](CC2=[F])c3ccccc3)c2n1 Chemical compound C=Cc1n[n]([C@@H](CC2=[F])c3ccccc3)c2n1 CJSNDSAMJUXZLL-NSHDSACASA-N 0.000 description 1
- YUQMYLFRASQUAS-UHFFFAOYSA-N CC(C)(C)[SH-](C)(C)OC(CC(c1nc(Br)n[n]1C1OCCCC1)O)c1ccccc1 Chemical compound CC(C)(C)[SH-](C)(C)OC(CC(c1nc(Br)n[n]1C1OCCCC1)O)c1ccccc1 YUQMYLFRASQUAS-UHFFFAOYSA-N 0.000 description 1
- CJGRUCNGYWCYJW-UHFFFAOYSA-N CC(C)(C)[Si+](C)(C)OC(CC(c1nc(Br)n[n]1C1OCCCC1)O)c1ccccc1 Chemical compound CC(C)(C)[Si+](C)(C)OC(CC(c1nc(Br)n[n]1C1OCCCC1)O)c1ccccc1 CJGRUCNGYWCYJW-UHFFFAOYSA-N 0.000 description 1
- RNODSKPBZYCWDX-BBRMVZONSA-N CC(C)c1c[n](-c2n[n]([C@@H](C[C@@H]3C)c4ccccc4)c3n2)nc1 Chemical compound CC(C)c1c[n](-c2n[n]([C@@H](C[C@@H]3C)c4ccccc4)c3n2)nc1 RNODSKPBZYCWDX-BBRMVZONSA-N 0.000 description 1
- LCZXCYYKYOZYHG-UHFFFAOYSA-N CCCc1n[n](C(CC2F)c3ccccc3)c2n1 Chemical compound CCCc1n[n](C(CC2F)c3ccccc3)c2n1 LCZXCYYKYOZYHG-UHFFFAOYSA-N 0.000 description 1
- KFTRBBAKMIQBGW-AAEUAGOBSA-N C[C@@H](C1)c2nc(-[n]3cnc(C(C)(F)F)c3)n[n]2[C@@H]1c1ccccc1 Chemical compound C[C@@H](C1)c2nc(-[n]3cnc(C(C)(F)F)c3)n[n]2[C@@H]1c1ccccc1 KFTRBBAKMIQBGW-AAEUAGOBSA-N 0.000 description 1
- JAENMDSHDMXIHY-AAEUAGOBSA-N C[C@@H](C1)c2nc(-[n]3nccc3)n[n]2[C@@H]1c1ccccc1 Chemical compound C[C@@H](C1)c2nc(-[n]3nccc3)n[n]2[C@@H]1c1ccccc1 JAENMDSHDMXIHY-AAEUAGOBSA-N 0.000 description 1
- NFEOYMVEFIVUAU-AAEUAGOBSA-N C[C@@H](C1)c2nc(COCC#N)n[n]2[C@@H]1c1ccccc1 Chemical compound C[C@@H](C1)c2nc(COCC#N)n[n]2[C@@H]1c1ccccc1 NFEOYMVEFIVUAU-AAEUAGOBSA-N 0.000 description 1
- SYIIYYDYEGITLS-UHFFFAOYSA-N FC(C1)c2nc(Br)n[n]2C1c1ccccc1 Chemical compound FC(C1)c2nc(Br)n[n]2C1c1ccccc1 SYIIYYDYEGITLS-UHFFFAOYSA-N 0.000 description 1
- SQKQCCLSQQAYBZ-BBRMVZONSA-N N#Cc1ccc2[n](-c3n[n]([C@@H](C[C@@H]4F)c5ccccc5)c4n3)nnc2c1 Chemical compound N#Cc1ccc2[n](-c3n[n]([C@@H](C[C@@H]4F)c5ccccc5)c4n3)nnc2c1 SQKQCCLSQQAYBZ-BBRMVZONSA-N 0.000 description 1
- MFEXKZYLIYDFOY-UHFFFAOYSA-N OC(C1)c2nc(Br)n[n]2C1c1ccccc1 Chemical compound OC(C1)c2nc(Br)n[n]2C1c1ccccc1 MFEXKZYLIYDFOY-UHFFFAOYSA-N 0.000 description 1
- GSXXASFBNUNZBP-UHFFFAOYSA-N OC(CC=O)c1ccccc1 Chemical compound OC(CC=O)c1ccccc1 GSXXASFBNUNZBP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570892P | 2017-10-11 | 2017-10-11 | |
| US62/570,892 | 2017-10-11 | ||
| PCT/EP2018/077656 WO2019072942A1 (en) | 2017-10-11 | 2018-10-10 | BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018348930A1 true AU2018348930A1 (en) | 2020-03-26 |
Family
ID=63840848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018348930A Abandoned AU2018348930A1 (en) | 2017-10-11 | 2018-10-10 | Bicyclic compounds for use as RIP 1 kinase inhibitors |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11673892B2 (https=) |
| EP (1) | EP3694858B1 (https=) |
| JP (1) | JP7362600B2 (https=) |
| KR (1) | KR20200070297A (https=) |
| CN (1) | CN111201229B (https=) |
| AU (1) | AU2018348930A1 (https=) |
| BR (1) | BR112020007067A2 (https=) |
| CA (1) | CA3078653A1 (https=) |
| CL (1) | CL2020000944A1 (https=) |
| CO (1) | CO2020004977A2 (https=) |
| CR (1) | CR20200151A (https=) |
| IL (1) | IL273443A (https=) |
| MA (1) | MA50356A (https=) |
| MX (1) | MX2020003439A (https=) |
| PE (1) | PE20211246A1 (https=) |
| PH (1) | PH12020550253A1 (https=) |
| RU (1) | RU2020114670A (https=) |
| SG (1) | SG11202003283TA (https=) |
| WO (1) | WO2019072942A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
| US11098058B2 (en) * | 2017-07-14 | 2021-08-24 | Genentech, Inc. | Bicyclic ketone compounds and methods of use thereof |
| SG11202002877RA (en) | 2017-10-31 | 2020-04-29 | Hoffmann La Roche | Bicyclic sulfones and sulfoxides and methods of use thereof |
| CN113302193A (zh) | 2019-01-11 | 2021-08-24 | 豪夫迈·罗氏有限公司 | 双环吡咯并三唑酮化合物及其使用方法 |
| CN114591333B (zh) * | 2020-12-04 | 2023-08-01 | 广州嘉越医药科技有限公司 | 一种吡咯并嘧啶类化合物的制备方法 |
| WO2023039795A1 (zh) * | 2021-09-16 | 2023-03-23 | 维泰瑞隆（北京）生物科技有限公司 | Rip1激酶抑制剂及其用途 |
| WO2025261418A1 (zh) * | 2024-06-19 | 2025-12-26 | 成都赜灵生物医药科技有限公司 | 并芳基类化合物及其用途 |
| WO2026001865A1 (en) * | 2024-06-24 | 2026-01-02 | Sironax Ltd. | Rip1 modulators, preparations, and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| AU8405691A (en) * | 1990-09-04 | 1992-03-30 | Yamanouchi Pharmaceutical Co., Ltd. | Novel tetrahydrobenzazole derivative |
| ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| EP1007042A4 (en) | 1997-06-13 | 2001-07-04 | Sugen Inc | NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| ES2349762T3 (es) | 2000-08-10 | 2011-01-11 | Pfizer Italia S.R.L. | Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden. |
| US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| EP1397364B1 (en) | 2001-05-24 | 2007-07-25 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
| JP4202250B2 (ja) | 2001-07-25 | 2008-12-24 | バイオマリン ファーマシューティカル インコーポレイテッド | 血液脳関門輸送を調節するための組成物および方法 |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| CN101284136A (zh) | 2002-12-03 | 2008-10-15 | 布朗歇特洛克菲勒神经科学研究所 | 传输物质穿过血脑屏障的人工低密度脂蛋白载体 |
| US20050089473A1 (en) | 2003-09-10 | 2005-04-28 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| NZ578876A (en) | 2007-02-07 | 2012-12-21 | Pfizer | 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors |
| JP2012051806A (ja) * | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | イミダゾリルピラジン誘導体 |
| JP2012532912A (ja) | 2009-07-15 | 2012-12-20 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | ガンマセクレターゼモジュレーターとしての置換されたトリアゾールおよびイミダゾール誘導体 |
| KR101913135B1 (ko) | 2011-07-15 | 2018-10-30 | 얀센 파마슈티칼즈, 인코포레이티드 | 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체 |
| EP2852584B1 (en) | 2012-05-22 | 2018-02-28 | F. Hoffmann-La Roche AG | Substituted dipyridylamines and uses thereof |
| CA2896187A1 (en) | 2013-01-18 | 2014-07-24 | F. Hoffmann-La Roche Ag | 3-substituted pyrazoles and use as dlk inhibitors |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| PH12019502378A1 (en) | 2013-05-01 | 2022-05-11 | Hoffmann La Roche | Biheteroaryl compounds and uses thereof |
| CA2907912A1 (en) | 2013-05-01 | 2014-11-06 | F. Hoffmann-La Roche Ag | C-linked heterocycloalkyl substituted pyrimidines and their uses |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| RU2017109122A (ru) | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| WO2016142310A1 (en) | 2015-03-09 | 2016-09-15 | F. Hoffmann-La Roche Ag | Tricyclic dlk inhibitors and uses thereof |
| TWI763630B (zh) | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| MA44007A (fr) * | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc | Inhibiteurs du récepteur interagissant avec protéine kinase 1 |
| KR102613433B1 (ko) | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
-
2018
- 2018-10-10 PE PE2020000378A patent/PE20211246A1/es unknown
- 2018-10-10 MX MX2020003439A patent/MX2020003439A/es unknown
- 2018-10-10 MA MA050356A patent/MA50356A/fr unknown
- 2018-10-10 CN CN201880066460.0A patent/CN111201229B/zh active Active
- 2018-10-10 KR KR1020207013188A patent/KR20200070297A/ko not_active Ceased
- 2018-10-10 AU AU2018348930A patent/AU2018348930A1/en not_active Abandoned
- 2018-10-10 CR CR20200151A patent/CR20200151A/es unknown
- 2018-10-10 SG SG11202003283TA patent/SG11202003283TA/en unknown
- 2018-10-10 WO PCT/EP2018/077656 patent/WO2019072942A1/en not_active Ceased
- 2018-10-10 RU RU2020114670A patent/RU2020114670A/ru unknown
- 2018-10-10 CA CA3078653A patent/CA3078653A1/en active Pending
- 2018-10-10 JP JP2020520532A patent/JP7362600B2/ja active Active
- 2018-10-10 EP EP18785936.8A patent/EP3694858B1/en active Active
- 2018-10-10 BR BR112020007067-0A patent/BR112020007067A2/pt not_active Application Discontinuation
-
2020
- 2020-03-19 IL IL273443A patent/IL273443A/en unknown
- 2020-04-08 CL CL2020000944A patent/CL2020000944A1/es unknown
- 2020-04-09 US US16/844,952 patent/US11673892B2/en active Active
- 2020-04-09 PH PH12020550253A patent/PH12020550253A1/en unknown
- 2020-04-23 CO CONC2020/0004977A patent/CO2020004977A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020003439A (es) | 2020-07-29 |
| JP2020536915A (ja) | 2020-12-17 |
| SG11202003283TA (en) | 2020-05-28 |
| US20200283446A1 (en) | 2020-09-10 |
| CL2020000944A1 (es) | 2020-08-21 |
| US11673892B2 (en) | 2023-06-13 |
| MA50356A (fr) | 2021-04-21 |
| CA3078653A1 (en) | 2019-04-18 |
| EP3694858B1 (en) | 2023-01-11 |
| CR20200151A (es) | 2020-05-23 |
| IL273443A (en) | 2020-05-31 |
| JP7362600B2 (ja) | 2023-10-17 |
| PH12020550253A1 (en) | 2021-02-22 |
| CN111201229B (zh) | 2024-08-23 |
| CO2020004977A2 (es) | 2020-05-05 |
| KR20200070297A (ko) | 2020-06-17 |
| RU2020114670A (ru) | 2021-11-12 |
| PE20211246A1 (es) | 2021-07-13 |
| CN111201229A (zh) | 2020-05-26 |
| EP3694858A1 (en) | 2020-08-19 |
| WO2019072942A1 (en) | 2019-04-18 |
| BR112020007067A2 (pt) | 2020-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3781571B1 (en) | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) | |
| US11673892B2 (en) | Bicyclic compounds for use as RIP1 kinase inhibitors | |
| US11607396B2 (en) | Bicyclic amide compounds and methods of use thereof | |
| US11834461B2 (en) | Bicyclic ketone compounds and methods of use thereof | |
| WO2019086494A1 (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
| US20250282788A1 (en) | Bicyclic ketone compounds and methods of use thereof | |
| HK40062362A (en) | Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof | |
| HK40062362B (en) | Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof | |
| HK40036919A (en) | Compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |